证券代码：301330 证券简称：熵基科技 公告编号：2025-065 熵基科技股份有限公司 关于开立闲置募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 为提高闲置募集资金使用效率，合理利用暂时闲置的募集资金，增加公司投 资收益和股东回报，熵基科技股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第十一次会议和第三届监事会第十次会议，审议通过 了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司 使用不超过人民币 80,000 万元（含本数）的部分暂时闲置募集资金（含超募资 金）进行现金管理，该使用额度及授权的有效期自公司董事会审议通过之日起 12 个月内有效，并在上述额度内滚动使用。具体内容详见公司于 2024 年 8 月 30 日 在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于使用部分暂时闲置募集 资金进行现金管理的公告》（公告编号：2024-040）。 一、开立闲置募集资金现金管理专用结算账户的情况 近日，公司新开立了闲置募集资金现金管理专 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth, driven by advancements from companies like Neuralink and recent breakthroughs in China, indicating a potential commercialization of BCI technology in the near future [2][4][5]. Group 1: Neuralink Developments - Neuralink has showcased its latest research and product development, with 7 participants currently using the device for an average of 50 hours per week, peaking over 100 hours [2]. - The company plans to implant devices in the speech cortex by the end of 2025 to decode silent speech from brain signals, and aims to increase electrode channels to 3,000 by 2026 to explore restoring vision [2][3]. - By 2028, Neuralink anticipates implanting over 25,000 electrodes to address mental health issues and explore integration with AI, potentially allowing humans to control robots directly [3]. Group 2: Market Potential and Growth - The global BCI market is projected to grow from $2.62 billion in 2024 to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - The BCI technology is recognized as one of the most disruptive technologies of the 21st century, with expectations for a surge in medical product applications over the next 5 to 10 years [4]. Group 3: Domestic Developments in China - Recent successful trials in China, including the first invasive BCI-assisted rehabilitation for a stroke patient, highlight the rapid advancement of BCI technology towards commercialization [4]. - The "Beijing Brain Institute" has developed a flexible, high-throughput, semi-invasive BCI system that has entered clinical trials, marking significant progress in the field [4]. Group 4: Industry Insights - The domestic BCI industry is benefiting from technological breakthroughs and supportive government policies, which are expected to accelerate the commercialization process [5]. - BCI products are categorized into non-invasive and invasive types, with non-invasive products leading in commercialization, while invasive products are still in clinical research stages [6]. - Despite the promising outlook, the BCI industry faces challenges related to safety, regulatory approval, and the need for foundational research [6][7].

证券代码：301330 证券简称：熵基科技 公告编号：2025-064 熵基科技股份有限公司 关于注销及开立闲置募集资金现金管理专用结算账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 三、投资风险及风险控制措施 （一）投资风险分析 1、虽然投资产品均经过严格的评估，但金融市场受宏观经济影响，不排除 该项投资受到市场波动的影响。 为提高闲置募集资金使用效率，合理利用暂时闲置的募集资金，增加公司投 资收益和股东回报，熵基科技股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日召开第三届董事会第十一次会议和第三届监事会第十次会议，审议通过 了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意公司及子公司 使用不超过人民币 80,000 万元（含本数）的部分暂时闲置募集资金（含超募资 金）进行现金管理，该使用额度及授权的有效期自公司董事会审议通过之日起 12 个月内有效，并在上述额度内滚动使用。具体内容详见公司于 2024 年 8 月 30 日 在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于使用部分暂时闲置 ...

Group 1 - A total of 24 companies were investigated by institutions on June 25, with 17 companies specifically targeted by funds [1][2] - The most popular company among funds was Botao Bio, which had 21 participating funds, followed by Sanfu Outdoor and Entropy Technology with 7 and 6 funds respectively [1][2] - The companies investigated belong to 12 different industries, with the textile and apparel, and pharmaceutical and biotechnology sectors having the most companies, each with 3 stocks listed [1] Group 2 - Among the companies investigated, 3 had a total market capitalization exceeding 50 billion yuan, while 13 had a market cap below 10 billion yuan [1] - In terms of market performance, 9 stocks among the investigated companies saw an increase in the last 5 days, with Haike Xinyuan, Bai'ao Intelligent, and Ganfeng Lithium leading with increases of 50.83%, 10.42%, and 5.88% respectively [1][2] - Conversely, 8 stocks experienced declines, with Mankalon, Botao Bio, and China Merchants Energy showing the largest drops of 7.94%, 5.35%, and 4.76% respectively [1][2]

Group 1: Company Overview and Business Strategy - The company aims to enhance market competitiveness through AI technology and brand influence, targeting revenue growth aligned with high equity incentive goals [2] - Focus on optimizing product and business structure, controlling costs, and improving operational efficiency to achieve performance growth [2] Group 2: Brain-Machine Interface (BMI) Technology - The company is exploring non-invasive BMI technology, particularly in the fields of elderly care, healthcare, and education [2][4] - Utilizes multi-modal data fusion technology ("EEG + EOG + EMG") to overcome precision limitations of traditional single-modal devices [2] Group 3: Applications in Education - Launching non-invasive brain-computer interface products aimed at enhancing focus among youth through interactive games and real-time EEG signal collection [3] Group 4: Partnerships and Collaborations - Established a long-term partnership with Workday to provide payroll calculation services for various sectors, enhancing operational efficiency for clients [5] Group 5: Mergers and Acquisitions - Ongoing audit of financial indicators related to the acquisition of "Longzhiyuan," with expectations of synergistic effects in product, technology, and market resources [6] Group 6: Ralvie AI Business Model - Ralvie AI focuses on work management and operational efficiency, quantifying employee work time and efficiency as a basis for performance evaluation [7] Group 7: Mars Wisdom Solutions - Mars Wisdom leverages advanced AI technologies to address semantic understanding, visual analysis, and data retrieval challenges, integrating with existing business platforms for enhanced service delivery [8] Group 8: Investor Relations Activity - The investor relations activity did not involve any undisclosed significant information [9]

A股市场热点不断，近期，"脑机接口"概念火了。 21世纪经济报道记者注意到，在上周大涨之后，6月23日，脑机接口板块继续上扬，塞力医疗 （603716）（603716.SH）"10CM"涨停，三博脑科（301293）（301293.SZ）涨幅超5%，佳禾智能 （300793）（300793.SZ）、麒盛科技（603610）（603610.SH）涨幅3%以上、诚益通（300430） （300430.SZ）、狄耐克（300884）（300884.SZ）、乐普医疗（300003）（300003.SZ）、熵基科技 （301330）（301330.SZ）涨幅2%以上。 与此同时，投资者涌向上市公司互动平台，密集询问公司脑机接口相关布局。从机构调研的角度看，近 两个月已有不少机构提前嗅到了相关机遇，了解脑机接口相关业务。 就脑机接口的产业链机遇而言，浙商证券（601878）指出，产业应用上，该市场仍以医疗为主。未来在 教育、游戏、智能家居等领域的应用占比将逐步提升。软件层面，人工智能技术的高速发展将为脑机接 口带来更多的创新机会；硬件层面，更高精度的传感器正在被开发，设备越来越轻便、便携，侵入性与 人体的兼容性正在持续改 ...

证券代码：301330 证券简称：熵基科技 公告编号：2025-062 熵基科技股份有限公司 关于持股 5%以上股东权益变动触及 1%整数倍的公告 股东深圳精英士君投资企业（有限合伙）及深圳精英和义投资企 业（有限合伙）保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 熵基科技股份有限公司（以下简称"公司"或"熵基科技"）于 2025 年 3 月 17 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减持股 份计划预披露公告》，公司持股 5%以上的股东深圳精英士君投资企业（有限合 伙）（以下简称"精英士君"）及深圳精英和义投资企业（有限合伙）（以下简 称"精英和义"）计划自减持计划预披露公告之日起十五个交易日后的三个月内， 分别以集中竞价和/或大宗交易方式减持公司股份不超过 2,886,600 股（不超过公 司剔除回购专用账户中股份数量后总股本的 1.4873%）。本次减持计划实施前， 精英士君持有公司股份 14,038,400 股，占公司总股本的 7.1511%；精英和义 ...

证券代码：301330 证券简称：熵基科技 公告编号：2025-063 熵基科技股份有限公司（以下简称"公司"）于 2025 年 4 月 21 日召开第三 届董事会第十七次会议、2025 年 5 月 15 日召开 2024 年年度股东大会，审议通 过了《关于变更注册资本及修改〈公司章程〉并办理工商登记变更手续的议案》， 具体内容详见公司于 2025 年 4 月 23 日在巨潮资讯网（http://www.cninfo.com.cn） 披露的《关于变更注册资本及修改〈公司章程〉并办理工商登记变更手续的公告》 （公告编号：2025-048）。 近日，公司完成了工商变更登记及修订后的《公司章程》备案，取得了东莞 市市场监督管理局核发的《营业执照》。现将相关情况公告如下： 一、公司注册资本变更相关情况 公司于 2025 年 6 月 4 日实施完成 2024 年年度权益分派方案，本次实施的权 益分派方案为：以截至 2025 年 6 月 3 日公司总股本 196,312,325 股扣除公司回购 专户中已回购股份 1,116,200 股后的股本 195,196,125 股为基数，向全体股东每 10 股转增 2 股。本次权益 ...

Group 1 - The core viewpoint of the news is that Shangji Technology (熵基科技) is currently experiencing a decline in stock price, with a closing price of 24.74 yuan and a drop of 5.28%, indicating it is in a state of post-IPO underperformance [1] - Shangji Technology was listed on the Shenzhen Stock Exchange's ChiNext board on August 17, 2022, with an initial issuance of 37.123 million shares, accounting for 25% of the total post-issue share capital, at an issue price of 43.32 yuan per share [1][2] - On its first trading day, the stock reached a peak price of 68.00 yuan but has since experienced a downward trend [2] Group 2 - The total amount raised by Shangji Technology during its IPO was 1.608 billion yuan, with a net amount of 1.457 billion yuan after deducting issuance costs, which was 147.64 million yuan more than the original plan [2] - The funds raised are intended for various projects, including the construction of a production base in Tangxia, a mixed biometric IoT smart industry base, a manufacturing facility in the United States, a research and development center, and a global marketing service network [2] - The total issuance costs (excluding VAT) amounted to 150.87 million yuan, with UBS Securities receiving 116.62 million yuan as underwriting and sponsorship fees [2] Group 3 - On May 25, 2023, Shangji Technology announced a dividend plan, proposing a stock bonus of 3 shares for every 10 shares held and a cash dividend of 3.5 yuan (pre-tax) [2] - The ex-dividend date was set for May 31, 2023, with the share registration date on May 30, 2023 [2] - At the 2024 annual general meeting scheduled for May 15, 2025, the company plans to distribute cash dividends of 5 yuan (including tax) for every 10 shares and to increase capital by transferring 2 shares for every 10 shares held, without issuing new shares [3]

Group 1 - The brain-computer interface sector has experienced a significant surge, with companies like Innovation Medical (002173) hitting the daily limit up [1] - Other companies such as Beikang, Aipeng Medical (300753), Nanjing Panda (600775), Entropy Technology (301330), and Sanbo Brain Science (301293) have also seen notable increases in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and activity [1]